Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Royalty PharmaRPRX +0.19%72 Net Cash per Share is $-25.26 as of Jun. 2026. GuruFocus rates RPRX with a GF Score™ of 72/100 and a GF Value™ of $41.59 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 744 Biotechnology companies, Royalty Pharma ranks worse than 134408.47% on this metric.
The historical rank and industry rank for Royalty Pharma's Net Cash per Share or its related term are showing as below:
RPRX's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.24 * Ranked among companies with meaningful Price-to-Net-Cash only.
Royalty Pharma (NAS:RPRX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Royalty Pharma Net Cash per Share Related Terms
Royalty Pharma Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPRX vs ROIV, INCY, INSM: Net Cash per Share Comparison
For the Biotechnology subindustry, Royalty Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Royalty Pharma's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (RPRX) has a Net Cash per Share of $-25.26 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #999999 out of 744 companies in the Biotechnology industry.
Is Royalty Pharma's Net Cash per Share too high?
Royalty Pharma's current Net Cash per Share is $-25.26. Based on the distribution chart, Royalty Pharma ranks #999999 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Royalty Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Net Cash per Share compare to ROIV and INCY?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #999999 out of 744 companies for Net Cash per Share. This places Royalty Pharma in the lower half of its industry. The industry median Net Cash per Share is 5.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.24, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Net Cash per Share is $-25.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (RPRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $41.59, compared to a current price of $61.90 — trading 48.8% above its estimated fair value. The current Net Cash per Share is $-25.26. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Royalty Pharma (RPRX), the current Net Cash per Share is $-25.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (RPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of $61.90 is trading 48.8% above its estimated GF Value™ of $41.59.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for RPRX:
Net Cash per Share: $-25.26
GF Value™: $41.59 vs. price of $61.90 (48.8% above fair value)
No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for RPRX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPRX has been successfully added to your 
